Pharma Unit Drives Bayer; Eylea Out-Performs
This article was originally published in Scrip
Executive Summary
Bayer AG's pharmaceutical division delivered strong sales in the third quarter, though blood thinner Xarelto (rivaroxaban) missed expectations.